What is behind Blood Sugar & Diabetes
Insulin sensitivity — how readily cells respond to insulin, the linchpin of metabolic health. Evidence B — Preclinical.
Fasting insulin — a sensitive marker of insulin resistance; chronically high levels signal metabolic strain. Evidence A — Human trial evidence.
The cell's master energy sensor — when fuel runs low it ignites fat-burning, glucose uptake and mitochondrial renewal while standing down growth. Evidence A — Human trial evidence.
Gut hormone for appetite control and steady blood sugar. Evidence A — Human trial evidence.
α-glucosidase — the intestinal enzyme that breaks dietary carbohydrate into absorbable glucose, setting the post-meal sugar spike. Evidence A — Human trial evidence.
Hepatic gluconeogenesis — the liver's manufacture of new glucose, which sets fasting blood-sugar. Evidence A — Human trial evidence.
The pancreatic cells that make insulin. Their functional reserve, not their number, is what fails first in type 2 diabetes — and reserve is partially recoverable, which is why this pathway exists separately from insulin. Evidence B — Preclinical.
Advanced glycation end-products — the sugar-damaged proteins that stiffen tissue and inflame the vessel wall. Evidence A — Human trial evidence.
GLUT4 is the transporter muscle moves to its surface to take glucose out of the blood — the step where disposal actually happens. Evidence B — Preclinical.
Insulin-receptor and PI3K–akt signaling — the anabolic line that clears glucose, supports the vessel wall and commands cell growth. Evidence A — Human trial evidence.
An adipose-derived hormone that sharpens insulin sensitivity and steers fat toward burning rather than storage. Evidence A — Human trial evidence.
Evidence on these pathways
AMPK → Insulin Sensitivity. “In model systems, sustained decreases in AMPK activity accompany IR, whereas AMPK activation increases insulin sensitivity.” — AMPK, insulin resistance, and the metabolic syndrome. The Journal of Clinical Investigation, 2013, volume 123, issue 7, pages 2764-2772. doi:10.1172/JCI67227
Pancreatic β-Cell → Fasting Insulin. “Pancreatic beta cells secrete insulin postprandially and during fasting to maintain glucose homeostasis.” — Genome-wide CRISPR screen identified a role for commander complex mediated ITGB1 recycling in basal insulin secretion. Molecular Metabolism, 2022, 63, 101541. doi:10.1016/j.molmet.2022.101541
Pancreatic β-Cell → Insulin Sensitivity. “Mechanistically, miR-26a in β cells enhances peripheral insulin sensitivity via exosomes.” — Pancreatic β cell microRNA-26a alleviates type 2 diabetes by improving peripheral insulin sensitivity and preserving β cell function. PLOS Biology, 2020, vol 18, e3000603. doi:10.1371/journal.pbio.3000603
Insulin Sensitivity → Women's Hormonal Balance. “A metabolic syndrome of obesity-related and/or intrinsic insulin resistance occurs in about half of PCOS patients, and the compensatory hyperinsulinism has tissue-selective effects, which include aggravation of hyperandrogenism.” — The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. Endocrine Reviews, 2016, 37(5), 467-520. doi:10.1210/er.2015-1104
Formulas that act on these pathways
Acts on 7 of these pathways: Insulin Sensitivity, Fasting Insulin, AMPK, α-Glucosidase Inhibition, Hepatic Gluconeogenesis, Pancreatic β-Cell, Advanced Glycation (AGEs).
Acts on 5 of these pathways: Insulin Sensitivity, AMPK, GLUT4 Muscle Glucose Uptake, Insulin-R / PI3K-AKT, Adiponectin.
Acts on 5 of these pathways: Insulin Sensitivity, Fasting Insulin, Pancreatic β-Cell, Advanced Glycation (AGEs), Insulin-R / PI3K-AKT.
Acts on 5 of these pathways: Insulin Sensitivity, Fasting Insulin, AMPK, Hepatic Gluconeogenesis, Adiponectin.
Acts on 5 of these pathways: Insulin Sensitivity, Fasting Insulin, AMPK, Hepatic Gluconeogenesis, Adiponectin.
Acts on 4 of these pathways: Insulin Sensitivity, Fasting Insulin, α-Glucosidase Inhibition, Advanced Glycation (AGEs).
What this page does not claim
This page names the pathways involved and the published evidence on each. It does not claim that any formula treats, cures or prevents Blood Sugar & Diabetes. A pathway opens here only on graded, published evidence, under a standard fixed before the evidence was gathered, and every figure above carries its grade.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.